Hormone Replacement Therapy After Risk-Reducing Surgery in Individuals at Increased Risk for Breast Cancer: The Patient Perspective
Surveys, Registries, Interviews
Survey for individuals with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D mutation
Study Contact Information:
Emily Stevens, estevens@gm.slc.edu,
289-689-3425
Erika Renkes, erenkes@gm.slc.edu,
815-441-5003
Jill Stopfer, JillE_Stopfer@dfci.harvard.edu
About the Study
In this study, we aim to better understand patient perceptions about hormone replacement therapy () and identify factors informing decision making about for use in individuals who have a , , , or genetic mutation that increases breast and ovarian cancer risk.
Individuals who have undergone risk-reducing surgery for ovarian cancer will be asked to complete a survey about their thoughts, experiences and understanding of the risks and benefits related to hormone replacement therapy.
This Study is Open To:
This study is open to:
- individuals who have undergone preventative surgical removal of BOTH ovaries AND (i.e., risk-reducing salpingo-oophorectomy) between the ages of 35 and 50 years old
- individuals with a confirmed , , , or genetic mutation
- individuals with no previous history of a breast cancer diagnosis
This Study is NOT Open To:
This study is not open to:
- individuals with a personal history of a breast cancer diagnosis
What the Study Involves
Participants will be asked to complete one online survey estimated to take about 15-20 minutes. There is no follow-up after completing the survey. Participation is voluntary and participants can choose to opt out of the study at any point without consequence. Participants also have the option to skip questions without justification. Survey responses will be kept anonymous and identifying information will not be shared. Every reasonable effort will be made to keep data secure. Participants will not receive monetary compensation. However, it is hoped this research will lead to a better understanding of factors influencing women’s decisions about and all participation is appreciated.
Lead Researchers
Emily Stevens, Genetic Counseling Student
Sarah Lawrence College, Bronxville, NY
Study Contact Information:
Emily Stevens, estevens@gm.slc.edu,
289-689-3425
Erika Renkes, erenkes@gm.slc.edu,
815-441-5003
Jill Stopfer, JillE_Stopfer@dfci.harvard.edu
Surveys, Registries, Interviews
Survey for individuals with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D mutation
Study Contact Information:
Emily Stevens, estevens@gm.slc.edu,
289-689-3425
Erika Renkes, erenkes@gm.slc.edu,
815-441-5003
Jill Stopfer, JillE_Stopfer@dfci.harvard.edu